Long-Acting Injectable PrEP for HIV: What Health Centers Need to Know
Year Developed: 2022
Resource Type: Archived Webinar.Primary Audience: Clinicians
Language(s): English
Developed by: National LGBTQIA+ Health Education Center at The Fenway Institute (See other resources developed by this organization).
Resource Summary: Long-acting injectable cabotegravir was approved for HIV pre-exposure prophylaxis in late 2021. In this interactive webinar, participants will learn about the effectiveness, advantages, and disadvantages of long-acting injectable cabotegravir as well as the clinical and programmatic steps to incorporate it into practice.
Resource Topic: Clinical Issues, Emerging Issues, Special and Vulnerable Populations
Resource Subtopic: HIV/AIDS.
Keywords: Access to Care, Education of - Staff (e.g., Competency-Based), Infectious Diseases.This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,625,000 with 0 percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.